Cyclacel Pharmaceuticals is a biotechnology business based in the US. Cyclacel Pharmaceuticals shares (CYCC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.39 – a decrease of 18.23% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.39 |
|---|---|
| 52-week range | $0.35 - $6.00 |
| 50-day moving average | $0.86 |
| 200-day moving average | $1.68 |
| Wall St. target price | $1.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-15.31 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.45 from 2024-11-13
| 1 week (2024-11-08) | -6.44% |
|---|---|
| 1 month (2024-10-15) | -44.68% |
| 3 months (2024-08-15) | -65.91% |
| 6 months (2024-05-15) | -81.56% |
| 1 year (2023-11-15) | 30.06% |
|---|---|
| 2 years (2022-11-15) | -97.34% |
| 3 years (2021-11-15) | 71.7 |
| 5 years (2019-11-15) | 117 |
| Revenue TTM | $80,000 |
|---|---|
| Gross profit TTM | $-455,000 |
| Return on assets TTM | -102.53% |
| Return on equity TTM | -570.69% |
| Profit margin | 0% |
| Book value | $0.57 |
| Market Capitalization | $846,039 |
TTM: trailing 12 months
We're not expecting Cyclacel Pharmaceuticals to pay a dividend over the next 12 months.
Cyclacel Pharmaceuticals's shares were split on a 1:15 basis on 17 December 2023 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclacel Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Cyclacel Pharmaceuticals shares which in turn could have impacted Cyclacel Pharmaceuticals's share price.
Over the last 12 months, Cyclacel Pharmaceuticals's shares have ranged in value from as little as $0.351 up to $6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclacel Pharmaceuticals's is 0.557. This would suggest that Cyclacel Pharmaceuticals's shares are less volatile than average (for this exchange).
Cyclacel Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.